Posted by Michael Wonder on 23 Jun 2026
Principles of broad (multi-cancer) listings for programmed cell death-1/programmed death ligand-1 (PD-(L)1) inhibitors
23 June 2026 - The Department has published a fact sheet ‘Principles for broad (multi-cancer) listings for programmed cell death-1/programmed death ligand-1 (PD-(L)1) inhibitors’.
This document is intended to outline the guiding principles for sponsors who may be seeking a broad (multi-cancer) listing for PD-(L)1 inhibitors.
Sponsors of PD-L(1) medicines are not required to seek a broad listing. Sponsors retain the ability to lodge submissions seeking PBS listings for specific indications in accordance with the Procedure guidance for listing medicines on the PBS and PBAC Guidelines.
